Activity of LaSOM 65, a monastrol-derived compound, against glioblastoma multiforme cell lines

Anticancer Research

Volumn 33, Issue 10, 2013, Pages 4463-4468

  Stuepp, Cristiane Santos ^a   Figueiró, Fabrício ^a   Mendes, Franciane Brackmann ^a   Braganhol, Elizandra ^a   Bernardi, Andressa ^a   Frozza, Rudimar Luiz ^a   Salbego, Christianne Gazzana ^a   Canto, Rômulo Faria Santos ^a   Russowsky, Dennis ^a   Eifler Lima, Vera Lucia ^a   Battastini, Ana Maria Oliveira ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Antitumor activity; Glioma; KSP inhibitors; LaSOM 65

Indexed keywords

ANTINEOPLASTIC AGENT; LACTATE DEHYDROGENASE; LASOM 65; MONASTROL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL COUNTING; CELL CYCLE ASSAY; CELL CYCLE G2 PHASE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; GLIOBLASTOMA; GLIOMA CELL; HIPPOCAMPUS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; NONHUMAN; PRIORITY JOURNAL; SLICE CULTURE; TUMOR CELL LINE;

ANTITUMOR ACTIVITY; GLIOMA; KSP INHIBITORS; LASOM 65;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL NUCLEUS; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; GLIOBLASTOMA; HIPPOCAMPUS; HUMANS; L-LACTATE DEHYDROGENASE; NECROSIS; PYRIMIDINES; RATS; THIONES; TISSUE CULTURE TECHNIQUES; TUBULIN;

EID: 84891348671     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY and Olson JJ: Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 60: 166-193, 2010.
2. Sathornsumetee S, Reardon DA, Desjardins A, Quinn JA, Vredenburgh JJ and Rich JN: Molecularly targeted therapy for malignant glioma. Cancer 110: 13-24, 2007.
3. Behin A, Hoang-Xuan K, Carpentier AF and Delattre JY: Primary brain tumours in adults. Lancet 361: 323-331, 2003.
4. Purcell JW, Davis J, Reddy M, Martin S, Samayoa K, Vo H, Thomsen K, Bean P, Kuo WL, Ziyad S, Billig J, Feiler HS, Gray JW, Wood KW and Cases S: Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancer. Clin Cancer Res 16: 566-576, 2010.
5. Carter BZ, Mak DH, Shi Y, Schober WD, Wang RY, Konopleva M, Koller E, Dean NM and Andreeff M: Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance. Cell Cycle 5: 2223-229, 2006.
6. Le Guellec R, Paris J, Couturier A, Roghi C and Philippe M: Cloning by differential screening of a Xenopus cDNA that encodes a kinesin-related protein. Mol Cell Biol 11: 3395-3398, 1991.
7. Mayer TU, Kapoor TM, Haggarty SJ, King RW, Schreiber SL and Mitchison TJ: Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 286: 971-974, 1999.
8. Canto RFS BA, Battastini AMO, Russowsky D, Eifler-Lima VL: Synthesis of Dihydropyrimidin-2-one/thione Library and Cytotoxic Activity against the Human U138-MG and Rat C6 Glioma Cell Lines. J Braz Chem Soc 22: 1379-1388, 2011.
9. Whitaker JF: A general colorimetric procedure for the estimation of enzymes which are linked to the NADH-NAD+ system. Clin Chim Acta 24: 23-37, 1969.
10. Stoppini L, Buchs PA and Muller D: A simple method for organotypic cultures of nervous tissue. J Neurosci Methods 37: 173-182, 1991.
11. Valentim LM, Rodnight R, Geyer AB, Horn AP, Tavares A, Cimarosti H, Netto CA and Salbego CG: Changes in heat shock protein 27 phosphorylation and immunocontent in response to preconditioning to oxygen and glucose deprivation in organotypic hippocampal cultures. Neuroscience 118: 379-386, 2003.
12. Leizerman I, Avunie-Masala R, Elkabets M, Fich A and Gheber L: Differential effects of monastrol in two human cell lines. Cell Mol Life Sci 61: 2060-70, 2004.
13. Kamal A, Shaheer Malik M, Bajee S, Azeeza S, Faazil S, Ramakrishna S, Naidu VG and Vishnuwardhan MV: Synthesis and biological evaluation of conformationally flexible as well as restricted dimers of monastrol and related dihydropyrimidones. Eur J Med Chem 46: 3274-81, 2011.
14. Torres BG, Uchoa FD, Pigatto MC, Azeredo FJ, Haas SE, Dallegrave E, Canto RF, Eifler-Lima VL and Dalla Costa T: Preclinical pharmacokinetics and acute toxicological evaluation of a monastrol derivative anticancer candidate LaSOM 65 in rats. Xenobiotica: 2013.
15. Chen Y, Chow JP and Poon RY: Inhibition of Eg5 acts synergistically with checkpoint abrogation in promoting mitotic catastrophe. Mol Cancer Res 10: 626-35, 2012.
16. Sashidhara KV, Avula SR, Sharma K, Palnati GR and Bathula SR: Discovery of coumarin-monastrol hybrid as potential antibreast tumor-specific agent. Eur J Med Chem 60: 120-127, 2013.